COSMO Pharmaceuticals N.V.
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-10 02:00 |
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
|
English | 10.6 KB | ||
| 2023-10-10 02:00 |
Cosmo reicht Zulassungsantrag für Winlevi® bei der Europäischen Arzneimittel-Ag…
|
German | 11.3 KB | ||
| 2023-10-02 02:00 |
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and No…
|
English | 14.2 KB | ||
| 2023-10-02 02:00 |
Cosmo und Hikma unterzeichnen Lizenzvertrag für Winlevi® in 17 Ländern des Nahe…
|
German | 15.4 KB | ||
| 2023-09-27 02:00 |
Cosmo and Glenmark announce the signing of Distribution and License Agreements …
|
English | 15.5 KB | ||
| 2023-09-27 02:00 |
Cosmo und Glenmark geben die Unterzeichnung von Vertriebs- und Lizenzvereinbaru…
|
German | 16.4 KB | ||
| 2023-09-04 02:00 |
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg …
|
English | 13.2 KB | ||
| 2023-09-04 02:00 |
Cosmo und Adalvo unterzeichnen Lizenz- und Liefervertrag für Rifamycin SV MMX® …
|
German | 13.9 KB | ||
| 2023-07-26 02:00 |
Cosmo presents strong H1 2023 operational and financial results
|
English | 35.0 KB | ||
| 2023-07-26 02:00 |
Cosmo mit starken operativen und finanziellen Ergebnissen im 1. Halbjahr 2023
|
German | 36.8 KB | ||
| 2023-07-05 02:00 |
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
|
English | 8.9 KB | ||
| 2023-07-05 02:00 |
Einladung zum Halbjahr 2023-Webcast von Cosmo am 26. Juli 2023
|
German | 9.3 KB | ||
| 2023-06-29 02:00 |
Cosmo announces the beginning of the phase III trials in males for the treatmen…
|
English | 15.3 KB | ||
| 2023-06-29 02:00 |
Cosmo kündigt Beginn der Phase-III-Studien bei Männern für die Behandlung von a…
|
German | 17.4 KB | ||
| 2023-06-28 02:00 |
Cosmo announces Cortiment® approval in Japan
|
English | 8.6 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for COSMO Pharmaceuticals N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
